QuidelOrtho Corporation (QDEL)

QuidelOrtho (QDEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

QDEL continues to witness growth on the back of its strong product portfolio.

Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has st...

Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.

QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and C...